Literature DB >> 32628788

Disruption of Sinonasal Epithelial Nrf2 Enhances Susceptibility to Rhinosinusitis in a Mouse Model.

Murugappan Ramanathan1, Anuj Tharakan1, Venkataramana K Sidhaye2,3, Andrew P Lane1, Shyam Biswal3, Nyall R London1.   

Abstract

OBJECTIVES/HYPOTHESIS: Oxidative stress has been postulated to play an important role in chronic rhinosinusitis. Nrf2 is a transcription factor that is involved in the regulation of multiple antioxidant genes, and its function has been previously shown to be important in sinonasal inflammation. Although the sinonasal implications of whole body Nrf2-/- has been reported, the function of sinonasal epithelial expression of Nrf2 has not been studied. The primary aim of this study was to generate a mouse model that is genetically deficient in epithelial-specific Nrf2 and to understand its role in regulating sinonasal inflammation. STUDY
DESIGN: Basic science.
METHODS: An epithelial-specific Nrf2 knockout mouse was generated by crossing Krt5-cre(K5) with Nrf2flox/flox . A papain-induced model of rhinosinusitis was performed in the resulting K5 Nrf2-/- mouse. Immunohistochemistry was performed to quantify goblet cell hyperplasia. Mucosal cellular infiltrates were quantified using flow cytometry, and tissue cytokines were measured using an enzyme-linked immunosorbent assay. Lastly, the cellular source of type 2 cytokines was determined using intracellular cytokine staining.
RESULTS: Papain-sensitized mice lacking epithelial-specific Nrf2 demonstrate increased goblet cell hyperplasia, significant tissue eosinophilia, and statistically significant increase in mucosal IL-13 when compared to Nrf2 wild-type mice. Lastly, mucosal T cells were identified as the cellular source of IL-13.
CONCLUSIONS: We demonstrate enhanced severity of eosinophilic sinonasal inflammation from disruption of the epithelial-specific Nrf2 pathway. The responsiveness of Nrf2-directed antioxidant pathways may act as a major determinant of susceptibility to eosinophilic inflammation and may have potential as a therapeutic target for chronic rhinosinusitis. LEVEL OF EVIDENCE: NA Laryngoscope, 131:713-719, 2021.
© 2020 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Nrf2; chronic rhinosinusitis; epithelial; mouse model; sinonasal

Mesh:

Substances:

Year:  2020        PMID: 32628788      PMCID: PMC7785671          DOI: 10.1002/lary.28884

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  28 in total

Review 1.  Molecular characterization of redox mechanisms in allergic asthma.

Authors:  Lan Jiang; Philip T Diaz; Thomas M Best; Julia N Stimpfl; Feng He; Li Zuo
Journal:  Ann Allergy Asthma Immunol       Date:  2014-06-27       Impact factor: 6.347

2.  Air pollutant-mediated disruption of sinonasal epithelial cell barrier function is reversed by activation of the Nrf2 pathway.

Authors:  Nyall R London; Anuj Tharakan; Ana M Rule; Andrew P Lane; Shyam Biswal; Murugappan Ramanathan
Journal:  J Allergy Clin Immunol       Date:  2016-07-27       Impact factor: 10.793

3.  Nrf2 activation via Keap1 deletion or sulforaphane treatment reduces Ova-induced sinonasal inflammation.

Authors:  Nyall R London; Anuj Tharakan; Michelle Mendiola; Mengfei Chen; Alex Dobzanski; Thomas E Sussan; Michael Zaykaner; Andrew H Han; Andrew P Lane; Venkataramana Sidhaye; Shyam Biswal; Murugappan Ramanathan
Journal:  Allergy       Date:  2019-06-14       Impact factor: 13.146

4.  Conditional deletion of Nrf2 in airway epithelium exacerbates acute lung injury and impairs the resolution of inflammation.

Authors:  Narsa M Reddy; Haranatha R Potteti; Thomas J Mariani; Shyam Biswal; Sekhar P Reddy
Journal:  Am J Respir Cell Mol Biol       Date:  2011-06-09       Impact factor: 6.914

Review 5.  Oxidative stress in patients with COPD.

Authors:  Stelios Loukides; Petros Bakakos; Konstantinos Kostikas
Journal:  Curr Drug Targets       Date:  2011-04       Impact factor: 3.465

6.  Role of STAT6 and mast cells in IL-4- and IL-13-induced alterations in murine intestinal epithelial cell function.

Authors:  Kathleen B Madden; Lucia Whitman; Carolyn Sullivan; William C Gause; Joseph F Urban; Ildy M Katona; Fred D Finkelman; Terez Shea-Donohue
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

7.  Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease.

Authors:  Masaru Suzuki; Tomoko Betsuyaku; Yoko Ito; Katsura Nagai; Yasuyuki Nasuhara; Kichizo Kaga; Satoshi Kondo; Masaharu Nishimura
Journal:  Am J Respir Cell Mol Biol       Date:  2008-06-19       Impact factor: 6.914

8.  Deletion of Nrf2 enhances susceptibility to eosinophilic sinonasal inflammation in a murine model of rhinosinusitis.

Authors:  Nyall R London; Anuj Tharakan; Michelle Mendiola; Thomas E Sussan; Mengfei Chen; Alex Dobzanski; Andrew P Lane; Venkataramana Sidhaye; Shyam Biswal; Murugappan Ramanathan
Journal:  Int Forum Allergy Rhinol       Date:  2018-10-03       Impact factor: 3.858

9.  Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53.

Authors:  A M Pierce; I B Gimenez-Conti; R Schneider-Broussard; L A Martinez; C J Conti; D G Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

10.  Spontaneous eosinophilic nasal inflammation in a genetically-mutant mouse: comparative study with an allergic inflammation model.

Authors:  Seok Hyun Cho; Sun Young Oh; Zhou Zhu; Joan Lee; Andrew P Lane
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

View more
  2 in total

Review 1.  Role of Environmental Air Pollution in Chronic Rhinosinusitis.

Authors:  Evelyn M Leland; Zhenyu Zhang; Kathleen M Kelly; Murugappan Ramanathan
Journal:  Curr Allergy Asthma Rep       Date:  2021-09-09       Impact factor: 4.919

2.  Primary Amine Modified Gold Nanodots Regulate Macrophage Function and Antioxidant Response: Potential Therapeutics Targeting of Nrf2.

Authors:  Yueh-Hsia Luo; Hsien-Jen Cheng; Feng-Yuan Tsai; Tsui-Chun Tsou; Shu-Yi Lin; Pinpin Lin
Journal:  Int J Nanomedicine       Date:  2020-10-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.